FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright

GRI Bio, Inc. (NASDAQ:GRI) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of GRI Bio in a research note issued to investors on Monday, April 14th. HC Wainwright analyst M. Keller now anticipates that the company will earn ($1.10) per share for the year, up from their prior estimate of ($15.31). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for GRI Bio’s FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.29) EPS and FY2028 earnings at ($0.23) EPS.

GRI Bio Stock Performance

NASDAQ GRI opened at $1.53 on Wednesday. GRI Bio has a one year low of $1.10 and a one year high of $130.39. The firm’s fifty day moving average is $5.58 and its two-hundred day moving average is $9.82. The firm has a market cap of $803,250.00, a PE ratio of -0.13 and a beta of -1.72.

Institutional Investors Weigh In On GRI Bio

An institutional investor recently raised its position in GRI Bio stock. Geode Capital Management LLC raised its stake in GRI Bio, Inc. (NASDAQ:GRI) by 543.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 76,182 shares of the company’s stock after acquiring an additional 64,335 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of GRI Bio worth $63,000 at the end of the most recent quarter. 33.95% of the stock is owned by institutional investors and hedge funds.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.